ERBB2 and breast cancer: Following the preliminary results of the SOPHIA trial (NCT02492711), it received Food and Drug Administration (FDA) approval in 2020 for patients with locally advanced or metastatic HER2+ BC who have previously undergone at least two anti-HER2 treatments, including one for metastatic disease [61].